EQT Infrastructure VI, through its indirectly owned subsidiary Otello BidCo AB, announces a recommended public offer to the shareholders of OX2 AB (publ) (“OX2”). The shares are admitted to trading on Nasdaq Stockholm, Large Cap.

OX2, founded in 2004, is a leading renewable energy platform with a large and diverse project portfolio across all major renewable energy technologies (onshore and offshore wind, solar, and storage) and is today one of the largest developers of onshore wind in Europe.

The total value of the offer is approximately SEK 16.4 billion.

Vinge’s team mainly consists of Sofie Bjärtun, Erik Sjöman, Linnéa Sellström, Joel Magnusson, Lorin Arabi and Maximilian Bengtsson (apital Markets and Public M&A), Christoffer Thalin, Peter Sundgren, Filip Öhrner, Daniel Daun, Niklas Törnell and Jonatan Karlsson (Energy, M&A), Sebastian Örndahl, Hampus Peterson, Lovisa Lewin and Ebba Ehrling Sjögren (Regulatory), Kamyar Najmi (Banking and finance), Lina Österberg, Tilda Hall and Agnes Pigg (Environment and Real Estate) Sam Seddigh and Alice Göransson (Employment), Fredrika Hjelmberg and Ian Linde (IT/GDPR), Gulestan Ali (Compliance) and Julia Ulander Kull (Transaction Support Coordinator).

 

Related

Vinge has advised Verisure in connection with its IPO on Nasdaq Stockholm

Vinge has advised Verisure plc (“Verisure”) in connection with its IPO on Nasdaq Stockholm. Following the publication of the prospectus on 29 September 2025, trading in Verisure’s shares commenced today, 8 October 2025.
October 08, 2025

Vinge has acted for Advania on the acquisition of smartvokat

smartvokat GmbH, a German-based consultancy specialising in digital transformation within the legal, risk, and compliance domains, will become part of Advania’s business unit Transformation & Automation.
October 08, 2025

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025